Zacks Investment Research lowered shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) from a hold rating to a sell rating in a research report released on Tuesday morning.

According to Zacks, “AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. “

Separately, Chardan Capital set a $15.00 price target on shares of Amicus Therapeutics and gave the stock a buy rating in a report on Thursday, August 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $12.19.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ:FOLD) opened at 7.24 on Tuesday. The firm’s market capitalization is $1.03 billion. Amicus Therapeutics has a one year low of $4.98 and a one year high of $11.78. The stock has a 50 day moving average of $7.26 and a 200 day moving average of $6.90.

Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by $0.07. Analysts forecast that Amicus Therapeutics will post ($1.35) earnings per share for the current year.

In other news, insider Perceptive Advisors Llc sold 1,100,000 shares of the company’s stock in a transaction dated Thursday, August 25th. The stock was sold at an average price of $6.81, for a total value of $7,491,000.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Hung Do sold 25,000 shares of the company’s stock in a transaction dated Tuesday, September 6th. The shares were sold at an average price of $7.00, for a total value of $175,000.00. Following the completion of the transaction, the insider now owns 583,453 shares in the company, valued at approximately $4,084,171. The disclosure for this sale can be found here. 3.40% of the stock is owned by insiders.

Several institutional investors have recently modified their holdings of FOLD. Teachers Advisors Inc. increased its position in Amicus Therapeutics by 1.0% in the first quarter. Teachers Advisors Inc. now owns 173,294 shares of the biopharmaceutical company’s stock worth $1,464,000 after buying an additional 1,750 shares in the last quarter. BlackRock Fund Advisors increased its position in Amicus Therapeutics by 1.6% in the first quarter. BlackRock Fund Advisors now owns 5,444,399 shares of the biopharmaceutical company’s stock worth $46,005,000 after buying an additional 83,654 shares in the last quarter. M&T Bank Corp purchased a new position in Amicus Therapeutics during the first quarter worth approximately $157,000. UBS Group AG increased its position in Amicus Therapeutics by 37.7% in the first quarter. UBS Group AG now owns 88,282 shares of the biopharmaceutical company’s stock worth $746,000 after buying an additional 24,155 shares in the last quarter. Finally, Squarepoint Ops LLC increased its position in Amicus Therapeutics by 101.9% in the first quarter. Squarepoint Ops LLC now owns 83,600 shares of the biopharmaceutical company’s stock worth $706,000 after buying an additional 42,200 shares in the last quarter. Institutional investors own 99.08% of the company’s stock.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

5 Day Chart for NASDAQ:FOLD

Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.